Eledoisin

69-25-0

C54H85N13O15S

H2O : 18.15 mg/mL (15.27 mM; Need ultrasonic and warming)

Others

Eledoisin is a specific agonist of NK2 and NK3 receptors. Sequence: {Glp}-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2. IC50 & Target: NK2 and NK3 receptors^[1]. In Vitro: Eledoisin increases the value recorded under basal conditions by 24.5+/-3.7%; this stimulation is significantly (P<0.01) lowered to 13.1+/-1.9% by the simultaneous presence of CP99994. The same protocol is also used to characterize the sensitivity of Eledoisin stimulation to 0.1 uM SR48968 or 0.1 uM SB222200. SR48968 significantly (P < 0.01) lower the stimulation by Eledoisin, while SB222200 has no effect. Eledoisin stimulation is reduced by CP99994 and SR48968, NK1 and NK2 antagonists, respectively^[1]. In Vivo: Eledoisin (0.1-1 nmol/kg) injected into rats produces a biphasic cardiovascular response that consists of an initial fall of systemic blood pressure (8-15 mm Hg) followed by a rise (20-22 mm Hg). Intracerebroventricular injection of Eledoisin produces an enhancement of grooming and scratching behavior in mice^[2].